Remibrutinib clears Phase III in RMS, setting up global filings for Novartis
NVS sits 31% above its 52-week low of $121.57.
Summary
Novartis announced positive Phase III REMODEL-1/-2 results for remibrutinib in relapsing multiple sclerosis, showing superiority over teriflunomide on relapse rate and disability endpoints with a favorable safety profile. The company plans global regulatory submissions.
Key Events · Product Development and Regulatory · NVS
-
Phase III RMS trials meet primary endpoint
REMODEL-1/-2 showed remibrutinib significantly reduced annualized relapse rate vs teriflunomide in ~2,000 patients with relapsing multiple sclerosis.
-
Superiority on all key secondary endpoints
Remibrutinib beat teriflunomide on MRI lesion reduction and showed clinically meaningful delay in disability progression (positive 3mCDP trend, nominally significant 6mCDP).
-
Favorable safety profile
No liver safety signal and no Hy's Law cases across the >4,500-patient development program, consistent with prior CSU data.
-
Global regulatory submissions planned
Novartis will present late-breaking data at MSToronto2026 and intends to seek approval for remibrutinib in RMS worldwide.
Analysis · NVS · Life Sciences
Positive topline results from two identical Phase III trials establish remibrutinib as a high-efficacy oral BTK inhibitor for relapsing multiple sclerosis, a market with nearly 3 million patients worldwide. The drug beat teriflunomide on the primary endpoint (annualized relapse rate) and all key secondary endpoints, including MRI lesions and disability progression, with no liver safety signal. Novartis plans global regulatory submissions, positioning remibrutinib as a potential blockbuster expansion beyond its existing CSU approval.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.8% of the 1864 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NVS was trading at $159.12 on NYSE in the Life Sciences sector, with a market capitalization of approximately $279.1B. The 52-week trading range was $121.57 to $170.46. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.